Alnylam Pharma (ALNY) Tops Q1 EPS by 65c

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.42), $0.65 better than the analyst estimate of ($2.07). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $23.65 million.

2019 Updated Financial Guidance

Alnylam is updating its 2019 annual non-GAAP R&D expenses to be in the range of $550 to $590 million and non-GAAP SG&A expenses to be in the range of $390 to $410 million. Both non-GAAP R&D and non-GAAP SG&A expenses exclude stock-based compensation expenses. The increase in non-GAAP R&D guidance of $30 million is due primarily to third party obligations based on assumed closing of the Regeneron collaboration during the second quarter.

The Company expects its current cash, cash equivalents, and marketable debt securities will support company operations for multiple years based upon its current operating plan.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M